Stock Ratings / Health Care / RADX / dividends

JAGX (31) NEUP (32) NCEL (39) MRKR (48) ⌘ Pro Terminal →

Radiopharm Theranostics Limited (RADX) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.12 +17.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.15

Radiopharm Theranostics Limited (RADX) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $16.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.15 (+2.96%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RADX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY RADX SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$1.13-8.8% Next Q

Q2 (-2Q)

Grade B-$1.03-1.9% Next Q

Q3 (-1Q)

Grade C+$1.01+10.9% Next Q

Current

Grade C-$1.12+0.5% Hist 90D α

Trajectory: B- (69) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RADX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, RADX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1.58) or 200D SMA ($3.67) invalidates the momentum regime and cuts Target Base ($1.14) toward Bear Floor ($0.89).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RADX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RADX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in RADX & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on RADX and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RADX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -73.77%▼ DESCENDING CHANNEL

2026-10-30O $1.09H $1.16L $1.08C $1.12VOL 8.9K

RES: $3.58SUP: $0.34SMA50: $1.58SMA200: $3.67

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RADX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RADX Butterfly Map → + Track RADX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RADX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RADX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RADX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RADX)

Health Care Rank #198 of 1016 ⚔️ JAGX vs RADX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RADX vs. JAGX, NEUP, NCEL, MRKR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Radiopharm Theranostics Limited (RADX) ranks #198 by composite RQD confidence (61/100, grade C-) and #851 by equity capitalization ($16.1M). Within this direct 5-issuer industry benchmark cohort, RADX leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. RADX currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RADX ACTIVE Radiopharm Theranostics Limited	C-	61/100	—	—	—	+17.52%	$16.1M	Benchmark Subject
JAGX Jaguar Health Inc.	E	31/100	—	67.2%	-35.0%	-2.86%	$15.9M	/jagx-vs-radx →
NEUP Neuphoria Therapeutics Inc.	E	32/100	—	—	-11.8%	-8.93%	$16.6M	/neup-vs-radx →
NCEL NewcelX Ltd.	D-	39/100	—	—	-35.0%	-0.30%	$15.5M	/ncel-vs-radx →
MRKR Marker Therapeutics Inc.	D	48/100	—	—	-35.0%	+1.00%	$16.8M	/mrkr-vs-radx →

2. RADX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Radiopharm Theranostics Limited (RADX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $16.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. RADX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RADX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Radiopharm Theranostics Limited (NASDAQ: RADX) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $1.12 (+17.52% 1D, market cap $16.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, RADX ranks #198 in composite RQD confidence.

How does RADX compare to JAGX and NEUP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RADX carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, JAGX (Jaguar Health Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.9M) and NEUP (Neuphoria Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -11.8%, cap $16.6M). Among the 5-stock peer group, RADX leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RADX?

For Radiopharm Theranostics Limited (RADX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #198 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RADX trading relative to its 50-day, 200-day, and 52-week technical levels?

RADX last traded at $1.12 (+17.52% on volume of 38,684 shares), positioning the stock -29.11% below its 50-day simple moving average ($1.58) and -69.48% below its 200-day simple moving average ($3.67). Across its 52-week range of $0.90 to $16.25, RADX sits at the 1.4% percentile with a 14-day RSI of 41.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.26).

RADX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does RADX pay a dividend and is it safe?

Radiopharm Theranostics Limited (RADX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: RADX RQD Cockpit RADX 12M Forecast RADX Earnings & Move RADX Dividends & DRIP RADX Insiders & 13F RADX Whale Options RADX Profit Sankey RADX News & Why